Document Detail


Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome?
MedLine Citation:
PMID:  17145645     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Insulin resistance is an important pathophysiological feature of the polycystic ovary syndrome (PCOS). Insulin resistance and its compensatory hyperinsulinemia contribute to the anovulation, hyperandrogenism, infertility and early pregnancy loss suffered by women with PCOS. Current evidence supports the role of metformin in the treatment of anovulation in PCOS, both in monotherapy and concomitantly with clomiphene in clomiphene-resistant patients. In addition, novel evidence suggests that insulin sensitizers may also play a role in reducing the risk of early pregnancy loss. The insulin-sensitizing agents available commercially include metformin, rosiglitazone and pioglitazone. Compared with the thiozolidinediones, metformin is the agent that has been most frequently studied in PCOS, and has the most favorable pregnancy safety profile. In conclusion, there is strong evidence supporting the use of metformin as a primary ovulatory agent in women with PCOS.
Authors:
Kai I Cheang; Susmeeta T Sharma; John E Nestler
Related Documents :
22900995 - Pregnancy outcome in women with peritoneal, ovarian and rectovaginal endometriosis: a r...
23174315 - How does the inclusion of twins conceived via fertility treatments influence the result...
8739735 - Ovarian hyperstimulation syndrome may be more likely if multiple pregnancy occurs follo...
15695975 - Pregnancy outcome after the use of an aromatase inhibitor for ovarian stimulation.
6385455 - Real-time ultrasonic scanning in the diagnosis of pregnancy and the determination of fe...
8070605 - Post-term pregnancies with normal cardiotocographs and amniotic fluid columns: the role...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology     Volume:  22     ISSN:  0951-3590     ISO Abbreviation:  Gynecol. Endocrinol.     Publication Date:  2006 Nov 
Date Detail:
Created Date:  2006-12-05     Completed Date:  2007-04-04     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8807913     Medline TA:  Gynecol Endocrinol     Country:  England    
Other Details:
Languages:  eng     Pagination:  595-604     Citation Subset:  IM    
Affiliation:
Department of Pharmacy, Virginia Commonwealth University, Richmond, Virginia 23298-0111, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anovulation / therapy
Clinical Trials as Topic
Female
Fertility Agents, Female / pharmacology*,  therapeutic use*
Humans
Infertility, Female / therapy
Insulin Resistance
Metformin / therapeutic use*
Polycystic Ovary Syndrome / drug therapy*
Pregnancy
Pregnancy Outcome
Chemical
Reg. No./Substance:
0/Fertility Agents, Female; 657-24-9/Metformin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Vulnerability assessment of New Jersey's food supply to invasive species: the New Jersey IMPORT proj...
Next Document:  Effects of sports training in adolescence on growth, puberty and bone health.